PUBCHEM ID | 999 |
Molecular Weight (g/mol) | 136.152 |
Molecular Formula | C8H8O2 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 2 |
IUPAC Name | Phenylaceticacid |
Canonical SMILES | O=C(O)Cc1ccccc1 |
PUBCHEM IUPAC INCHIKEY | WLJVXDMOQOGPHL-UHFFFAOYSA-N |
Solubility Level | 4 |
Vapour Pressure | -2.461 |
XLOGP3 AA | NA |
CACTVS TPSA | 17.07 |
BBB Level | 2 |
Absorption Level | 0 |
EXT PPB#Prediction | 1 |
AlogP98 | 1.494 |
EXT CYP2D6#Prediction | 0 |
Mouse Female FDA | Non-Carcinogen |
Mouse Male FDA | Single-Carcinogen |
Rat Female FDA | Non-Carcinogen |
Rat Male FDA | Non-Carcinogen |
Ames Prediction | Non-Mutagen |
Developmental / Reproductive Toxicity | Toxic |
Rat Oral LD50 | 0.641377 |
Ocular Irritancy | Severe |
Hepatotoxic#Prediction | 0 |
Effected Human Genes | NA |
Aerobic Biodegradability Prediction | Degradable |
Physical hazards | not classified |
Health hazards | Mild |
Environmental hazards | not classified |
Serial No. | Cas No | Gene Symbol | Organism | Interaction | Interaction Actions | PubMed Id |
---|---|---|---|---|---|---|
1 | 103-82-2 | PON1 | Homo sapiens | [Ascorbic Acid co-treated with Copper Sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid] | affects^cotreatment|decreases^reaction|increases^hydrolysis | 15375178 |
2 | 103-82-2 | PON1 | Homo sapiens | [Ascorbic Acid co-treated with ferrous sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid] | affects^cotreatment|decreases^reaction|increases^hydrolysis | 15375178 |
Serial No. | Activity Name | Details | References (PubMed) | Other details EPA (U.S) | Clinical Trials (U.S. NIH) |
---|---|---|---|---|---|
1 | 103-82-2 | Benzylcarboxylic acid |